GLP-1 receptor agonists are currently among the most widely discussed classes of drugs worldwide. They have gained popularity for their effectiveness in treating type 2 diabetes and obesity, but increasing evidence suggests their effects may be much broader. Recent studies indicate that they may also influence inflammatory processes responsible for the development of many skin diseases.
